Joseph E. Gilliam Sells 5,000 Shares of Glaukos Corp (GKOS) Stock

Glaukos Corp (NYSE:GKOS) CFO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $70.03, for a total value of $350,150.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of NYSE:GKOS traded down $1.31 during trading on Thursday, reaching $68.01. The stock had a trading volume of 201,402 shares, compared to its average volume of 316,346. Glaukos Corp has a 1-year low of $26.75 and a 1-year high of $70.91.

Separately, Zacks Investment Research downgraded Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Glaukos has an average rating of “Buy” and an average price target of $58.20.

Several large investors have recently modified their holdings of GKOS. Oppenheimer Asset Management Inc. acquired a new stake in shares of Glaukos in the fourth quarter worth approximately $31,000. NumerixS Investment Technologies Inc boosted its stake in shares of Glaukos by 20.7% in the fourth quarter. NumerixS Investment Technologies Inc now owns 1,100 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 189 shares during the last quarter. Rehmann Capital Advisory Group acquired a new stake in shares of Glaukos in the third quarter worth approximately $63,000. Strs Ohio acquired a new stake in shares of Glaukos in the fourth quarter worth approximately $78,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Glaukos by 24.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,583 shares of the medical instruments supplier’s stock worth $145,000 after acquiring an additional 508 shares during the last quarter. 99.12% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2019/02/21/joseph-e-gilliam-sells-5000-shares-of-glaukos-corp-gkos-stock.html.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Recommended Story: Hedge Funds Explained

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply